Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT04462796 Recruiting - Clinical trials for Restless Legs Syndrome

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)

RLS
Start date: July 10, 2020
Phase: N/A
Study type: Interventional

The expected results of this study will have a significant impact on the treatment of RLS/WED patients. Magnesium supplementation (if proven to be beneficial) can be utilized as an inexpensive, safer, biologically plausible alternative to dopamine agonists and α2δ calcium-channel ligands.

NCT ID: NCT04436081 Recruiting - Alzheimer Disease Clinical Trials

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

Start date: February 26, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

NCT ID: NCT04408755 Recruiting - Clinical trials for Agitation in Patients With Dementia of the Alzheimer's Type

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Start date: July 8, 2020
Phase: Phase 3
Study type: Interventional

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

NCT ID: NCT04347668 Recruiting - Moderate Dementia Clinical Trials

Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Dementia is a term used to describe a collection of symptoms including memory loss, problems with reasoning and communication, and a reduction in a person's ability to carry out daily activities. The most common types of dementia are: Alzheimer's disease, vascular dementia, mixed dementia and dementia with Lewy bodies. Clinicians and families are looking for ways to deal with this challenging group of diseases to improve quality of life, reduce depression and agitation for individuals in long term care (LTC). There are a variety of non-pharmacologic interventions for dementia often used in addressing physiological and behavioral challenges, new to this category of treatment is virtual reality (VR). Virtual reality has been studied in mild cognitive impairment. Colleagues completed a systematic review of non-pharmacological intervention to treat older people with dementia and found music to be the only intervention effective, VR was not included as no studies were found. The Registered Nurses Association of Ontario report non-pharmacological approaches are an important alternative to the use of antipsychotic medications. They recommend health-care providers should consider non-pharmacological interventions wherever possible as a first-line approach to the management of BPSD. Virtual reality as proposed in this research will include music, library items will be selected that are person specific, and will provide sensory stimulation. To date there is no published research on the use the VR in moderate to severe dementia in LTC, looking at depression.

NCT ID: NCT04312893 Recruiting - Delirium Clinical Trials

The Effectiveness of Acupuncture for Delirium in Critically Ill Patients

Start date: March 12, 2020
Phase: N/A
Study type: Interventional

Introduction: Intensive care unit (ICU) delirium is an acute onset of brain dysfunction, which can affect 25-80% of ICU patients. Delirium is also associated with long term cognition impairment, higher mortality and higher ICU costs. Previous acupuncture studies showed the potential to prevent delirium. This study will examine the ability of acupuncture to treat ICU delirium. Methods: A double-blind randomized control trial will examine the effect of press tack acupuncture vs. press tack placebos. The patients will be randomly divided (1:1) into one of two groups. A total of 80 ICU patient will have to meet the following criteria: age 20-90, APACHE score <30, Intensive Care Delirium Screening Checklist (ICDSC) >4 points (indicates existing delirium), Richmond Agitation-Sedation Scale (RASS): +1, +2, +3, +4, -1, -2. Three interventions will be given in each group. The main outcomes will be the delirium days according to the ICDSC.

NCT ID: NCT04145674 Recruiting - Clinical trials for Restless Legs Syndrome

A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo

Glu-REST
Start date: October 22, 2022
Phase: Phase 2
Study type: Interventional

Proof of concept, double-blind, randomized, placebo-controlled trial with d-methadone proposed for the first time for use in the treatment of patients diagnosed with primary, moderate to very severe Restless Legs Syndrome (RLS). Its glutamatergic mechanism of action might be effective on RLS arousal pattern and sleep disturbance which highly impair the quality of life of RLS's patients. Patients will take the study drug/placebo once a day for 30 consecutive days.

NCT ID: NCT04144790 Recruiting - ADHD Clinical Trials

Impact of Iron Supplementation Treatment on Brain Iron Concentrations

Start date: September 15, 2022
Phase:
Study type: Observational

The goal of the present study is to provide novel data to evaluate brain iron concentration as a mediator of the association between iron supplementation treatment and improvement in symptoms of ADHD and RLS in children, including PLMS. Twelve participants between the ages of 10 and 15 years will be recruited via Kennedy Krieger Institute's Sleep Disorders Clinic. Eligible participants will be asked to complete, at baseline (pre-iron supplementation treatment) and again at follow-up (post-treatment): 1) a 7 Tesla MRI scan, 2) five consecutive nights of RestEaZe™ monitoring, 3) caregiver-reported (or patient-reported if over the age of 10 years) International Restless Leg Syndrome Scale (IRLSS), and 4) caregiver-reported ADHD Rating Scale-5. The treatment interval will be 3 months.

NCT ID: NCT04142840 Recruiting - Emergence Agitation Clinical Trials

Dexmedetomidine and Propofol in the Treatment of Emergence Agitation

Start date: November 1, 2019
Phase: Early Phase 1
Study type: Interventional

1. This clinical research aims to compare the effects of dexmedetomidine and propofol on the treatment of emergence agitation in adult patients after general anesthesia. 2. Half of participants will receive dexmedetomidine while the other half will receive propofol when emergence agitation happens.

NCT ID: NCT04094779 Recruiting - Dementia Clinical Trials

Effect of "Breath of Fresh Air" Flash Activity on Dementia Agitation : Pilot Study

DEMACTIFLASH
Start date: September 20, 2019
Phase: N/A
Study type: Interventional

Non-drug therapies (NDT) constitute a strong axis of the person with dementia behaviour management. Among these NDT, the flash activities constitute a mode of intervention to prevent and control the expression of the most disruptive behavior. These are short-term activities with the objective of decreasing the behavioural disorders intensity in less than 15 minutes. The aim of this pilot study is to test the effect of a flash activity "breath of fresh air" compared to the usual relational care on the short-term decrease (15 min.) of the agitation in hospitalized dementia patients.

NCT ID: NCT04075435 Recruiting - Anxiety Clinical Trials

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

CBD
Start date: January 11, 2021
Phase: Early Phase 1
Study type: Interventional

This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).